Recent News

• 09.24.2025 - Presentation – Bank of America Global Healthcare Conference
• 09.23.2025 - Fireside Chat – Bernstein’s 2nd Annual Healthcare Forum
• 09.17.2025 - Brepocitinib in DM
• 09.17.2025 - Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
• 09.11.2025 - Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
• 09.09.2025 - Fireside Chat – H.C. Wainwright Global Investment Conference
• 09.08.2025 - Fireside Chat – Morgan Stanley Annual Global Healthcare Conference
• 09.04.2025 - Fireside Chat –Wells Fargo Healthcare Conference
• 09.03.2025 - Immunovant Batoclimab Graves' Disease Proof-of-Concept Study Remission Data
• 09.03.2025 - Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Recent Filings

• 09.17.2025 - 8-K Current report
• 09.17.2025 - EX-99.1 EX-99.1
• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2025 - 8-K Current report
• 09.05.2025 - 4 Statement of changes in beneficial ownership of securities